and 41.9 respectively. SF-36 bodily pain, social functioning, and emotional domain mean scores were 57.5, 62.9, and 63.2 respectively. Of the PSC cohort, 57% (n= 157) reported that SpA has been or currently is a major problem in their life, and 74% (n= 204) were concerned about possible medication side-effects. ConClusions: This analysis shows that SpA represents a considerable burden to both patients and society overall in Mexico and Brazil. It further highlights the need for effective therapies to control both peripheral and axial Spondyloarthritis.

provide RWD on the use of BV in the treatment of HL in a private healthcare setting in Brazil. Methods: This retrospective analysis collected data from Evidencias-Kantar Health claims database (Auditron, which covers 3+ million lives, ~7% of Brazilian private sector) between March/2013-March/2016 on demographic, diseaserelated and treatment-related parameters regarding patients diagnosed with HL. Data were summarized using descriptive statistics. Results: We found 147 HL patients, being 51.7% female, with median age of 32 years (IQR:25-41). The number of patients that received each therapy line was: 147, 42, 29, 20, 9, 5, 3, 2 and 1 for first to ninth-line respectively. From the third-line forward, BV was present among the chosen therapies. Of the 15 patients treated with BV (1 patient received it in 3 lines), 60% were male, 43% on stage IV disease, had a median age of 30 years (IQR:28-39) and a median number of cycles of 3 (IQR:3-4). Distribution of patients (number of patients/total number of patients per line) that received BV in each line was: thirdline (1/20); fourth-line (7/20, with one patient receiving BV in combination with gemcitabine+liposomal doxorubicin); fifth-line (4/9); sixth-line (3/5); seventh-line (1/3); eighth-line (1/2). Overall, 10.2% of the patients with HL were treated with BV and only one received SCT (heterologous) in fourth-line. ConClusions: RWD from this cohort of HL from Auditron demonstrates 20% of patients with HL received at least 3 lines of treatment. The rate of patients treated with BV increased, as the lines of therapy advanced and 10.2% received the drug at some point in treatment.

No abstract

A879from 90.1% (1L) and 87.5% (2L) APACs could be decoded. Most used drug combinations reported for 1L-treatment were cyclophosphamide monotherapy (8.6%), cycl ophosphamide+dexamethasone+thalidomide (7.7%) and melphalane+prednisone (4.9%); for 2L-treatment, cyclophosphamide monotherapy (9.7%), bortezomibe (6.3%) cyclophosphamide+dexamethasone+thalidomide (5.2%) were the most frequent. ConClusions: The most reported drug was a monotherapy not included in the PCDT recommendations, all other frequent combinations were coherent with the current PCDT. The results found are limited by the uncertainty in data input in the database.